Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label study of ASC16 + ritonavir-boosted ASC08 (± ribavirin) in adults with chronic hepatitis C
CTR20190330Phase 3Active
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ravidasvir, danoprevir, ritonavir, ribavirin in hepatitis C virus infection, sponsored by Ascletis Pharma Inc.. Started Jul 2019; status: active.
02
Drugs
ravidasvirdanoprevirritonavirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20190330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190330.